Wake-Promoting and EEG Spectral Effects of Modafinil After Acute or Chronic Administration in the R6/2 Mouse Model of Huntington’s Disease

Neurotherapeutics - United States
doi 10.1007/s13311-020-00849-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

White Adipose Tissue Browning in the R6/2 Mouse Model of Huntington’s Disease

PLoS ONE
Multidisciplinary
2016English

Up-Regulation of GLT1 Reverses the Deficit in Cortically Evoked Striatal Ascorbate Efflux in the R6/2 Mouse Model of Huntington’s Disease

Journal of Neurochemistry
BiochemistryMolecular NeuroscienceCellular
2012English

Corticosterone Dysregulation Exacerbates Disease Progression in the R6/2 Transgenic Mouse Model of Huntington's Disease

Experimental Neurology
Developmental NeuroscienceNeurology
2016English

Author Correction: Laquinimod Treatment in the R6/2 Mouse Model

Scientific Reports
Multidisciplinary
2019English

Neurophysiological and Behavioral Effects of Anti-Orexinergic Treatments in a Mouse Model of Huntington’s Disease

Neurotherapeutics
NeurologyPharmacology
2019English

Ubiquilin-1 Overexpression Increases the Lifespan and Delays Accumulation of Huntingtin Aggregates in the R6/2 Mouse Model of Huntington's Disease

PLoS ONE
Multidisciplinary
2014English

CD200 Is Up-Regulated in R6/1 Transgenic Mouse Model of Huntington's Disease

PLoS ONE
Multidisciplinary
2019English

Altered Cortical Glutamate Receptor Function in the R6/2 Model of Huntington's Disease

Journal of Neurophysiology
NeurosciencePhysiology
2006English

XJB-5-131-mediated Improvement in Physiology and Behaviour of the R6/2 Mouse Model of Huntington's Disease Is Age- And Sex- Dependent

PLoS ONE
Multidisciplinary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy